A novel fragment derived from the Β chain of human fibrinogen, Β43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo

British Journal of Cancer

Volumn 102, Issue 3, 2010, Pages 594-601

  Krajewska, E ^a   Lewis, C E ^a   Chen, Y Y ^a   Welford, A ^a   Tazzyman, S ^a   Staton, C A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

43 63; Anti angiogenic; Endothelial; Fibrinogen; Haemostasis

Indexed keywords

ALANYLARGINYLPROLYLALANYLLYSYLALANYLALANYLALANYLTHREONYLGLUTAMINYLLYSYLLYSYLVALY LGLUTAMYLARGINYLLYSYLALANYLPROLYLASPARTYLALANINE; AMINO ACID; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 4; FIBRINOGEN; FIBRONECTIN; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BETA CHAIN; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADULT; AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL ADHESION; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBRINOGEN; HUMANS; MICE; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76349094691     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605495     Document Type: Article

References (32)

1. Beckstead J (1994) A simple technique for preservation of fixation sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 42: 1127-1134
2. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE (2000) Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 60: 4719-4724
3. Borges E, Jan Y, Ruoslahti E (2000) Platelet derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 275: 39867-39873
4. Brown NJ, Staton CA, Rodgers GR, Corke KP, Underwood JCE, Lewis CE (2002) Fibrinogen E-fragment selectively disrupts the vasculature and inhibits the growth of tumors in a synergic murine model. Br J Cancer 86: 1813-1816
5. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA (2004) Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 94: 316-323
6. Collingridge HAS, Chaplin DJ (2001) Proportion of infiltrating IgG binding immune cells predict for tumour hypoxia. Br J Cancer 84: 626-630
7. Daly ME, Makris A, Reed M, Lewis CE (2003) Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 95: 660-673
8. Delaney CE, Weagant BT, Addison CL (2006) The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Exp Cell Res 312: 2476-2489
9. Doolittle R (1981) Fibrinogen and fibrin. Sci Am 245: 92-101
10. Eliceiri BP (2001) Integrin and growth factor receptor crosstalk. Circ Res 89: 1104-1110
11. Ellis IR, Schor AM, Schor SL (2007) EGF and TGF-alpha motogenic activities are mediated by the EGF receptor via distinct matrix-dependent mechanisms. Exp Cell Res 313: 732-741
12. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1: 27-31
13. Hynes RO (2007) Cell-matrix adhesion in vascular development. J Thromb Haemost 5: 32-40
14. Kemp LE, Mulloy B, Gherardi E (2006) Signalling by HGF/SF and Met: the role of heparin sulphate co-receptors. Biochem Soc Trans 34: 414-417
15. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR (1986) Basement membrane complexes with biological activity. Biochemistry 25: 312-318
16. Kucharzewska P, Welch JE, Svensson KJ, Belting M (2009) The polyamines regulate endothelial cell survival during hypoxic stress through PI3K/ AKT and MCL-1. Biochem Biophys Res Commun 380: 413-418
17. Maeshima Y, Colorado PC, Kalluri R (2000) Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275: 23745-23750
18. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-143
19. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R (2001) Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 276: 31959-31968
20. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells. Exp Cell Res 250: 168-173
21. Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222: 124-138
22. Mundel TM, Kalluri R (2007) Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74: 85-89
23. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ (1994) Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5: 89-97
24. Park K, Kim YS, Lee GY, Park RW, Kim IS, Byun Y (2008) Tumour endothelial targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumour growth. Pharm Res 25: 2786-2798
25. Rüegg C, Mariotti A (2003) Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 60: 1135-1157
26. Sahni A, Francis CW (2004) Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 104: 3635-3641
27. Saito Y, Shiota Y, Nishisaka M, Owaki T, Shimamura M, Fukai F (2008) Inhibition of angiogenesis by a tenascin-c peptide which is capable of activating beta1-integrins. Biol Pharm Bull 31: 1003-1007
28. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F (1999) Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor 2. EMBO J 18: 882-892
29. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, Lewis CE (2004) Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103: 601-606
30. Yakovlev S, Gorlatov S, Ingham K, Medved L (2003) Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin binding site. Biochemistry 42: 709-716
31. Yokoyama K, Zhang XP, Medved L, Takada Y (1999) Specific binding of integrin alpha v beta 3 to the fibrinogen gamma and alpha E chain C-terminal domains. Biochemistry 38: 5872-5877
32. Zacharski LR, Memoli VA, Rousseau SM (1986) Coagulation-cancer interaction in situ in renal cell carcinoma. Blood 68: 394-399